Kaiyang Ding

1.1k total citations
51 papers, 241 citations indexed

About

Kaiyang Ding is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Kaiyang Ding has authored 51 papers receiving a total of 241 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 23 papers in Hematology and 20 papers in Pathology and Forensic Medicine. Recurrent topics in Kaiyang Ding's work include Lymphoma Diagnosis and Treatment (16 papers), Multiple Myeloma Research and Treatments (13 papers) and CAR-T cell therapy research (12 papers). Kaiyang Ding is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Multiple Myeloma Research and Treatments (13 papers) and CAR-T cell therapy research (12 papers). Kaiyang Ding collaborates with scholars based in China, United States and Canada. Kaiyang Ding's co-authors include Zhou Yuan, Xiaoyan Wang, Zimin Sun, Juan Tong, Xin Liu, Liangquan Geng, Huilan Liu, Xu Zhang, Xingbing Wang and Huanhuan Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Agricultural and Food Chemistry.

In The Last Decade

Kaiyang Ding

41 papers receiving 238 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kaiyang Ding China	9	113	107	100	46	36	51	241
Ryan J. Stubbins Canada	9	80 0.7×	102 1.0×	94 0.9×	43 0.9×	37 1.0×	26	286
Sung‐Soo Yoon South Korea	9	91 0.8×	152 1.4×	120 1.2×	35 0.8×	34 0.9×	54	272
Elizabeth Budde United States	9	161 1.4×	88 0.8×	105 1.1×	48 1.0×	63 1.8×	26	275
Fatima Zahra Jelloul United States	8	63 0.6×	92 0.9×	61 0.6×	23 0.5×	29 0.8×	32	172
Kiyoshi Okazuka Japan	11	108 1.0×	180 1.7×	160 1.6×	87 1.9×	43 1.2×	36	340
Vittorio Del Fabro Italy	9	93 0.8×	134 1.3×	100 1.0×	25 0.5×	23 0.6×	32	263
Yaozhong Zhao China	10	146 1.3×	219 2.0×	152 1.5×	26 0.6×	27 0.8×	20	314
Miki Kiyota Japan	10	93 0.8×	104 1.0×	137 1.4×	101 2.2×	107 3.0×	23	319
Raphael Teipel Germany	8	72 0.6×	137 1.3×	59 0.6×	30 0.7×	17 0.5×	21	196
Seo-Yeon Ahn South Korea	7	73 0.6×	123 1.1×	51 0.5×	65 1.4×	21 0.6×	26	215

Countries citing papers authored by Kaiyang Ding

Since Specialization

Citations

This map shows the geographic impact of Kaiyang Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaiyang Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaiyang Ding more than expected).

Fields of papers citing papers by Kaiyang Ding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaiyang Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaiyang Ding. The network helps show where Kaiyang Ding may publish in the future.

Co-authorship network of co-authors of Kaiyang Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Kaiyang Ding. A scholar is included among the top collaborators of Kaiyang Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaiyang Ding. Kaiyang Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Xinyang, Yifan Zheng, Haojie Jin, et al.. (2025). Hydrolyzed chicken meat extract and its effective cyclopeptides promote neurodevelopment by activating dopamine D1 receptor and cAMP/PKA/CREB pathway. Food Bioscience. 72. 107452–107452.

Ding, Kaiyang, Hailing Liu, Haiyan Yang, et al.. (2024). A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma. Med. 5(11). 1393–1401.e2. 6 indexed citations

Li, Chunrui, Dehui Zou, He Huang, et al.. (2024). Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study. Blood. 144(Supplement 1). 4761–4761. 2 indexed citations

Zhao, Weili, Jun Zhu, Yuqin Song, et al.. (2024). Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.. Journal of Clinical Oncology. 42(17_suppl). LBA7003–LBA7003. 7 indexed citations

Jin, Song, Junling Zhuang, Xin Zhou, et al.. (2024). Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study. Blood. 144(Supplement 1). 6970–6970.

Gao, Xiang, Anthony J. Olszanski, Gerald S. Falchook, et al.. (2024). 996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation. Annals of Oncology. 35. S678–S679. 1 indexed citations

Jin, Jie, Liling Zhang, Liqun Zou, et al.. (2024). Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26). Blood. 144(Supplement 1). 6368–6368.

Ding, Kaiyang, Hailing Liu, Lixia Sheng, et al.. (2024). Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial. European Journal of Cancer. 214. 115155–115155.

Wang, Di, Lugui Qiu, Keshu Zhou, et al.. (2024). P-094 The Optimal Lymphodepletion Prior to Eque-cel in Patients with Refractory Relapsed Multiple Myeloma in FUMANBA-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S96–S97.

10.

Yuan, Yanggang, Yan Jin, John Wang, et al.. (2023). 106P Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies. Annals of Oncology. 34. S1512–S1512. 8 indexed citations

11.

Ding, Kaiyang, Xiaoyong Wang, Chen Huang, et al.. (2023). Effectivness and Safety of Orelabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective, Real-World Study in China. Blood. 142(Supplement 1). 6552–6552.

12.

Jin, Jie, Qingqing Cai, Liling Zhang, et al.. (2023). Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26). Blood. 142(Supplement 1). 4430–4430. 3 indexed citations

13.

Cai, Qingqing, Jun Zhu, Yuqin Song, et al.. (2023). Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).. Journal of Clinical Oncology. 41(16_suppl). 7503–7503. 1 indexed citations

14.

Li, Chunrui, Di Wang, He Huang, et al.. (2023). CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1).. Journal of Clinical Oncology. 41(16_suppl). 8025–8025. 20 indexed citations

15.

Ding, Kaiyang, Jie Ma, Chunling Wang, et al.. (2023). High Rates of Remission with the Initial Treatment of Oral Selinexor Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes Analysis of a Multi-Center Phase II Study in China. Blood. 142(Supplement 1). 1696–1696. 1 indexed citations

16.

Yu, Lu, et al.. (2023). Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma. Cancer Medicine. 12(9). 10553–10562. 2 indexed citations

17.

Wang, Xiaoyan, Zhou Yuan, & Kaiyang Ding. (2021). Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications (Review). International Journal of Oncology. 59(1). 27 indexed citations

18.

Li, Jing, Li Bao, Zhongjun Xia, et al.. (2020). Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Annals of Hematology. 99(11). 2589–2598. 19 indexed citations

19.

Yang, Yingxue, et al.. (2018). Relationship between dynamic changes of Epstein-Barr virus and efficacy of lymphoma. 27(6). 336–339. 1 indexed citations

20.

Zheng, Changcheng, Baolin Tang, Juan Tong, et al.. (2013). Unrelated cord blood transplantation for central nervous system relapse in high-risk childhood acute lymphoblastic leukemia. Annals of Hematology. 92(12). 1665–1673. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact